Literature DB >> 15885218

Re-organization of P2X3 receptor localization on epidermal nerve fibers in a murine model of cancer pain.

Laura S Gilchrist1, David M Cain, Catherine Harding-Rose, Anh N Kov, Gwen Wendelschafer-Crabb, William R Kennedy, Donald A Simone.   

Abstract

To determine whether ATP and P2X3 receptors contribute to bone-cancer pain in a mouse model, immunohistochemical techniques were used to identify whether changes in the labeling of P2X3 receptors on epidermal nerve fibers (ENFs) occurred during tumor development. C3H mice were injected with osteolytic fibrosarcoma cells in and around the calcaneus bone. These mice exhibited mechanical hyperalgesia by day 10 post-implantation as assessed using von Frey monofilaments. Biopsies of the plantar skin overlying the tumor were obtained at days 10, 14, and 18 post-implantation. Confocal images were analyzed for the number of PGP 9.5, P2X3, and CGRP immunoreactive (ir) ENFs. The overall ENF population (PGP-ir) decreased progressively over time, whereas the subsets of P2X3-ir fibers demonstrated a modest increase and CGRP-ir nerve fibers remained fairly constant. Importantly, the proportion of CGRP-ir fibers that labeled for P2X3 increased from approximately 6% in control animals to nearly 30% at day 14 following tumor cell implantation. These studies demonstrate increased expression of P2X3 receptors on CGRP-ir ENFs during tumor growth and suggest a role for ATP in cancer-related pain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15885218     DOI: 10.1016/j.brainres.2005.02.081

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  29 in total

1.  TRPC1 contributes to light-touch sensation and mechanical responses in low-threshold cutaneous sensory neurons.

Authors:  Sheldon R Garrison; Alexander Dietrich; Cheryl L Stucky
Journal:  J Neurophysiol       Date:  2011-11-09       Impact factor: 2.714

Review 2.  Pharmacology of P2X channels.

Authors:  Joel R Gever; Debra A Cockayne; Michael P Dillon; Geoffrey Burnstock; Anthony P D W Ford
Journal:  Pflugers Arch       Date:  2006-04-29       Impact factor: 3.657

3.  Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia.

Authors:  Darryl T Hamamoto; Subhalakshmi Giridharagopalan; Donald A Simone
Journal:  Eur J Pharmacol       Date:  2006-12-09       Impact factor: 4.432

Review 4.  P2X3 receptor involvement in pain states.

Authors:  Kerstin Wirkner; Beata Sperlagh; Peter Illes
Journal:  Mol Neurobiol       Date:  2007-07-17       Impact factor: 5.590

Review 5.  Purinergic signalling in the musculoskeletal system.

Authors:  Geoffrey Burnstock; Timothy R Arnett; Isabel R Orriss
Journal:  Purinergic Signal       Date:  2013-08-14       Impact factor: 3.765

6.  Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain.

Authors:  Iryna A Khasabova; Anisha Chandiramani; Catherine Harding-Rose; Donald A Simone; Virginia S Seybold
Journal:  Pharmacol Res       Date:  2011-04-02       Impact factor: 7.658

Review 7.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

8.  P2X receptors in sensory neurons co-cultured with cancer cells exhibit a decrease in opioid sensitivity.

Authors:  I Chizhmakov; N Mamenko; T Volkova; I Khasabova; D A Simone; O Krishtal
Journal:  Eur J Neurosci       Date:  2008-12-11       Impact factor: 3.386

9.  The non-selective cannabinoid receptor agonist WIN 55,212-2 attenuates responses of C-fiber nociceptors in a murine model of cancer pain.

Authors:  M L Uhelski; D M Cain; C Harding-Rose; D A Simone
Journal:  Neuroscience       Date:  2013-05-11       Impact factor: 3.590

10.  Tumor-evoked sensitization of C nociceptors: a role for endothelin.

Authors:  Darryl T Hamamoto; Sergey G Khasabov; David M Cain; Donald A Simone
Journal:  J Neurophysiol       Date:  2008-08-06       Impact factor: 2.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.